Down-regulation of tumor necrosis factor alpha activity by acute ethanol treatment in human peripheral blood monocytes.
As the most commonly used drug that can modulate both metabolic and immune pathways, ethanol is evaluated in this report as a regulator of tumor necrosis factor alpha (TNF alpha) production in human peripheral blood monocytes (M phi) in combination with a variety of stimuli. While acute ethanol treatment did not induce TNF alpha in M phi, it was a potent down-regulator of M phi TNF alpha production whether induced by the combination of interferon-gamma plus muramyl dipeptide (MDP) (P < 0.001), lipopolysaccharide (LPS) alone (P < 0.01), or interferon-gamma plus LPS. Down-regulation of M phi TNF alpha by ethanol was dose dependent and statistically significant in the biologically relevant, 25-150 mM, ethanol concentration range. We also demonstrate that these ethanol concentrations did not affect M phi viability. TNF alpha down-regulation by ethanol was most effective when ethanol was administered 4 hr prior to MDP stimulation; however, it was also effective--though to a lesser extent--if it was added at the time of MDP stimulation. Furthermore, ethanol also down-regulated TNF alpha production of the in vivo preactivated M phi of trauma patients, which produce hyperelevated levels of TNF alpha. We have previously shown that the majority of posttrauma elevated M phi TNF alpha is produced by the M phi subpopulation expressing high-affinity type I Fc gamma receptors (Fc gamma RI). When the Fc gamma RI cross-linking-stimulated M phi subpopulation was treated with acute ethanol, TNF alpha production was suppressed again both in in vivo preactivated M phi of trauma patients and in M phi of normal controls.(ABSTRACT TRUNCATED AT 250 WORDS)
Verma
B K
BK
Department of Surgery, University of Massachusetts Medical Center, Worcester 01655.
Fogarasi
M
M
Szabo
G
G
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000494:pharmacology; D000328:Adult; D000368:Aged; D002448:Cell Adhesion; D002469:Cell Separation; D002470:Cell Survival; D015232:Dinoprostone / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation / Q000187:drug effects; D000431:Ethanol / Q000032:analysis / Q000494:pharmacology*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D007371:Interferon-gamma / Q000494:pharmacology; D008262:Macrophage Activation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000737:chemistry / Q000166:cytology / Q000378:metabolism*; D017452:Receptors, IgG / Q000032:analysis; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism / Q000502:physiology*
D017452:Receptors, IgG; D014409:Tumor Necrosis Factor-alpha; D000431:Ethanol; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D007371:Interferon-gamma; D015232:Dinoprostone; D007213:Indomethacin